UNION is a privately held, clinical stage, pharmaceutical company dedicated to the development of a class of molecules exhibiting both immunomodulatory and microbiological effects. UNION is focused on the treatment of inflammatory skin diseases, but the chemistry platform and its versatile modes of action are widely applicable across a wide range of diseases.

The company has raised funds through non-dilutive sources, the European Investment Bank as well as private investors.

For more information, please contact: 

Morten Boesen, CFO

+45 2381 5487